cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cymabay Therapeutics Inc
20 own
34 watching
Current Price
$0
$0.1
(1.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
788.38M
52-Week High
52-Week High
11.22
52-Week Low
52-Week Low
1.81
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization788.38M
icon52-Week High11.22
icon52-Week Low1.81
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Cymabay Therapeutics Inc do?
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Read More
How much money does Cymabay Therapeutics Inc make?
News & Events about Cymabay Therapeutics Inc.
Globe Newswire
1month ago
NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 ...
Ticker Report
2 months ago
CymaBay Therapeutics (NASDAQ:CBAY Get Rating) had its price target lifted by HC Wainwright from $10.00 to $12.00 in a research note published on Friday, The Fly reports. Other equities research analysts also recently issued research reports about the company. Raymond James increased their ...
Ticker Report
3 months ago
CymaBay Therapeutics, Inc. (NASDAQ:CBAY Get Rating) Equities research analysts at Oppenheimer boosted their FY2024 earnings per share estimates for CymaBay Therapeutics in a research report issued to clients and investors on Monday, March 6th. Oppenheimer analyst J. Olson now expects...
Globe Newswire
3 months ago
NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd...
Globe Newswire
4 months ago
NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities ...
Frequently Asked Questions
Frequently Asked Questions
What is Cymabay Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cymabay Therapeutics Inc shares?
plus_minus_icon
How can I buy Cymabay Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cymabay Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cymabay Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cymabay Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cymabay Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cymabay Therapeutics Inc?
plus_minus_icon
What percentage is Cymabay Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cymabay Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.1
(1.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00